ReviewNature reviews. Rheumatology2022
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.
Review in Nature reviews. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 305 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
305 citing papers in PubMed, 9 syntheses or guidelines pooled it, 556 citations in OpenAlex.
- New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review.Dermatology and therapy · 2026Pooled it
- French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Guideline
- IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.Frontiers in immunology · 2026Pooled it
- Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review.Rheumatology international · 2025Pooled it
- Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis.Current hypertension reports · 2024Pooled it
- Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review.Rheumatology international · 2024Pooled it
- Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.Annals of the rheumatic diseases · 2024Guideline
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026 · on this mapTrial
- Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial.Arthritis research & therapy · 2026Trial
- Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.Rheumatology (Oxford, England) · 2026Trial
- Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.Rheumatology (Oxford, England) · 2026Trial
- Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.Rheumatology (Oxford, England) · 2026Trial
- Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.Nature medicine · 2025Trial
- Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.Arthritis research & therapy · 2025Trial
- Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.American journal of clinical dermatology · 2025Trial
- The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis.Arthritis research & therapy · 2025Trial
- Trial
245 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
34 authors at 19 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have advanced considerably. This work reviews the literature since the previous recommendations (data published 2013-2020, including conference presentations between 2017 and 2020) and reports high-quality, evidence-based, domain-focused recommendations for medication selection in PsA developed by GRAPPA clinicians and patient research partners. The overarching principles for the management of adults with PsA were updated by consensus. Principles considering biosimilars and tapering of therapy were added, and the research agenda was revised. Literature searches covered treatments for the key domains of PsA: peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail psoriasis; additional searches were performed for PsA-related conditions (uveitis and inflammatory bowel disease) and comorbidities. Individual subcommittees used a GRADE-informed approach, taking into account the quality of evidence for therapies, to generate recommendations for each of these domains, which were incorporated into an overall schema. Choice of therapy for an individual should ideally address all disease domains active in that patient, supporting shared decision-making. As safety issues often affect potential therapeutic choices, additional consideration was given to relevant comorbidities. These GRAPPA treatment recommendations provide up-to-date, evidence-based guidance on PsA management for clinicians and people with PsA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.